Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer.

ABSTRACT:

Background

Lazertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that demonstrated progression-free survival (PFS) benefit in treatment-naive, EGFR-mutant advanced non-small-cell lung cancer (NSCLC) as a single agent and in combination with amivantamab. Here, we report the clinical efficacy and safety profile of lazertinib plus stereotactic body radiotherapy (SBRT) in treatment-naive, EGFR-mutant oligometastatic NSCLC.

Patients and methods

ABLATE is a phase II, multicenter, randomized, non-comparative study that included patients harboring activating EGFR mutations (ex19del or L858R) with synchronous oligometastatic disease (metastatic lesion ≤5). Patients received oral lazertinib 240 mg as monotherapy or in combination with

SUBMITTER: Lee JB 

PROVIDER: S-EPMC12874586 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature